Questcor Pharmaceuticals Beats Up on Analysts Yet Again
Questcor Pharmaceuticals (NAS: QCOR) reported earnings on Feb. 22. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Questcor Pharmaceuticals beat expectations on revenues and beat expectations on earnings per share.
Compared with the prior-year quarter, revenue improved significantly and GAAP earnings per share grew significantly.
Margins expanded across the board.
Questcor Pharmaceuticals tallied revenue of $75.5 million. The six analysts polled by S&P Capital IQ expected revenue of $71.5 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $29.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.48. The seven earnings estimates compiled by S&P Capital IQ anticipated $0.40 per share. GAAP EPS of $0.48 for Q4 were 433% higher than the prior-year quarter's $0.09 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 94.7%, 60 basis points better than the prior-year quarter. Operating margin was 56.6%, 1,970 basis points better than the prior-year quarter. Net margin was 41.9%, 2,000 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $98.9 million. On the bottom line, the average EPS estimate is $0.40.
Next year's average estimate for revenue is $450.1 million. The average EPS estimate is $1.84.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 363 members out of 396 rating the stock outperform, and 34 members rating it underperform. Among 114 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 100 give Questcor Pharmaceuticals a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Questcor Pharmaceuticals is buy, with an average price target of $50.93.
The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Questcor Pharmaceuticals the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.
- Add Questcor Pharmaceuticals to My Watchlist.
At the time this article was published
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.